奥曲肽对新生儿坏死性小肠结肠炎患儿粪便性状及体液免疫的影响  

Effects of octreotide on fecal characteristics and humoral immunity in neonates with necrotizing enterocolitis

作　　者：张婕 苗耐英 李欢 刘新建 ZHANG Jie;MIAO Naiying;LI Huan;LIU Xinjian(Department of Pediatrics,Hebei PetroChina Central Hospital,Langfang 065000,China)

机构地区：[1]河北中石油中心医院儿科,065000

出　　处：《天津医药》2024年第12期1331-1334,共4页Tianjin Medical Journal

基　　金：廊坊市科技支撑计划项目(2023013037)。

摘　　要：目的观察奥曲肽对新生儿坏死性小肠结肠炎(NEC)患儿粪便性状及体液免疫的影响。方法回顾性选取2022年3月—2023年9月在河北中石油中心医院新出生的60例NEC患儿,依据治疗方法将患儿分成观察组(30例)和常规组(30例)。常规组给予全胃肠外营养和胃肠减压加哌拉西林钠他唑巴坦钠治疗,治疗7 d;观察组在常规治疗基础上附加奥曲肽治疗,治疗5 d。比较2组患儿治疗效果、一般临床资料、肠道菌群紊乱程度、肠道菌群标志物和免疫指标表达水平。结果观察组治疗总有效率高于常规组(P<0.05)。治疗后,观察组患儿体质量高于常规组,住院时间、呕吐缓解时间、腹胀缓解时间、腹泻缓解时间和粪便性状完全恢复时间均短于常规组。与治疗前相比,2组患儿治疗后肠道菌群紊乱程度和高迁移率族蛋白B1(HMGB1)均降低,人β防御素2(HBD2)、自诱导分子-2(AI-2)和血清免疫球蛋白(Ig)A、IgG、IgM表达水平均升高(P<0.05);且观察组HMGB1低于常规组,HBD2、AI-2和血清IgA、IgG、IgM高于常规组(P<0.05)。结论奥曲肽可有效治疗NEC患儿,改善粪便性状,提高免疫力。Objective To observe the effects of octreotide on fecal characteristics and humoral immunity in neonates with necrotizing enterocolitis(NEC).Methods A retrospective study was conducted on 60 newly born NEC patients at Hebei PetroChina Central Hospital from March 2022 to September 2023.The patients were separated into the observation group(30 cases)and the routine group(30 cases)based on treatment methods.The conventional group was treated with total parenteral nutrition and gastrointestinal decompression plus piperacillin sodium and tazobactam sodium for 7 days.The observation group was treated with octreotide in addition to the routine group for 5 days.The treatment efficacy,general clinical data,degree of intestinal microbiota disorder,expression levels of intestinal microbiota markers and immune indicators were compared between the two groups.Results The total effective rate of the observation group was higher than that of the routine group(P<0.05).After treatment,body weight of the observation group was higher than that of the routine group.The hospitalization time,vomiting relief time,abdominal distension relief time,diarrhea relief time and complete recovery time of fecal characteristics were lower in the observation group than those in the routine group.Compared with before treatment,the degree of intestinal microbiota disorder and high mobility group box protein 1(HMGB1)were reduced in both groups after treatment,and expression levels of humanβdefensin 2(HBD2),autoinducer-2(AI-2)and serum immunoglobulin(Ig)A,IgG and IgM were increased(P<0.05).After treatment,HMGB1 was lower in the observation group than that in the routine group,while HBD2,AI-2 and serum IgA,IgG and IgM were higher than those in the routine group(P<0.05).Conclusion Octreotide can effectively treat children with NEC,improve stool characteristics,and enhance immunity.

关 键 词：小肠结肠炎 坏死性 婴儿 新生 奥曲肽 免疫 体液 粪便性状 

分 类 号：R725.7[医药卫生—儿科]